The asthma market in the EU5 is highly competitive. Many approved agents are available, including maintenance therapies\u2014LABA\/ICS FDCs (e.g., GSK\u2019s Seretide and Relvar, AstraZeneca\u2019s Symbicort, branded generics and generics), ICSs (e.g., AstraZeneca\u2019s Pulmicort, Teva\u2019s Qvar), leukotriene inhibitors, biologics (e.g., Novartis\u2019s Xolair, GSK\u2019s Nucala, AstraZeneca\u2019s Fasenra), and a LAMA (Boehringer Ingelheim\u2019s Spiriva, generics)\u2014and rescue therapies, such as SABAs (e.g., GSK\u2019s Ventolin, Teva\u2019s ProAir). Understanding patient pathways and drivers of treatment decisions for key players in asthma can help optimize these agents\u2019 uptake and provide valuable insights for developers of novel brands entering the market.<\/p>\n
QUESTIONS ANSWERED<\/p>\n
\u00b7\u00a0What patient share do key drug classes and individual therapies garner in intermittent, mild, moderate, and\/or severe asthma?<\/p>\n
\u00b7\u00a0Which main factors influence treatment practices in asthma? What is the sequencing of treatment for asthma? What do physicians report as recent and anticipated changes in their treatment practices?<\/p>\n
\u00b7\u00a0What are the main reasons why certain eligible patients do not receive asthma biologics? What features drive the choice of a biologic in asthmatics?<\/p>\n
\u00b7\u00a0Which features drive the choice of a LABA\/ICS FDC agent? What are the main obstacles to prescribing individual branded and generic LABA\/ICS FDCs?<\/p>\n
\u00b7\u00a0What are the compliance and persistency rates for key products on the market?<\/p>\n
PRODUCT DESCRIPTION<\/p>\n
Current Treatment: Physician Insights\u00a0provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n
Geographies<\/strong>\u00a0<\/strong><\/p>\n EU5 (Germany, France, Spain, Italy, United Kingdom).<\/p>\n Primary Research<\/strong><\/p>\n Survey of 250 European pulmonologists.<\/p>\n Key Drugs Covered<\/strong><\/p>\n Seretide, Symbicort, Relvar, Formodual \/ Foster, Flutiform, Spiriva, Xolair, Nucala, Cinqaero, Fasenra, Dupixent, montelukast.<\/p>\n Key Insights<\/strong><\/p>\n\n